当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-11-06 , DOI: 10.1111/apt.16669 Anne Flint 1 , Grit Andersen 2 , Paul Hockings 3, 4 , Leona Plum-Mörschel 2 , Rohit Loomba 5
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-11-06 , DOI: 10.1111/apt.16669 Anne Flint 1 , Grit Andersen 2 , Paul Hockings 3, 4 , Leona Plum-Mörschel 2 , Rohit Loomba 5
Affiliation
This article is linked to Flint et al papers. To view these articles, visit https://doi.org/10.1111/apt.16608 and https://doi.org/10.1111/apt.16641
中文翻译：
社论：GLP-1 受体激动剂作为糖尿病和肥胖以外 NASH 药物疗法的演变——作者的回复
本文链接到 Flint 等人的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.16608 和 https://doi.org/10.1111/apt.16641
更新日期：2021-11-07
中文翻译：
社论：GLP-1 受体激动剂作为糖尿病和肥胖以外 NASH 药物疗法的演变——作者的回复
本文链接到 Flint 等人的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.16608 和 https://doi.org/10.1111/apt.16641
京公网安备 11010802027423号